OVERVIEW

Genetics in Clinical Cancer Care: From Family Reunions to the Frontline of Developmental Therapeutics is organized by Meeting Achievements, LLC and will be held from Apr 17 - 19, 2020.

Accreditation:

Physician Credit
The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 17.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Genetic Counselor Credit
The National Society of Genetic Counselors (NSGC) has authorized University of Chicago Pritzker School of Medicine to offer up to 1.635 CEUs or 16.35 Category 1 contact hours for the activity 9th Annual Clinical Cancer Genetics and Genomics Conference. The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of genetic counselor certification and recertification.

American Board of Internal Medicine MOC Part II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Description:
This activity will provide an interdisciplinary educational forum in which to update state-of-the-art science including novel therapies for inherited cancers, discuss real-world cases, curate interesting pedigrees, and prepare case summaries to disseminate new knowledge in translational genomics and evidence-based clinical management of high-risk patients and their family members.

Objectives:
At the conclusion of this activity, participants will be able to:
• Recall advanced concepts in genetics, genomics, and next generation sequencing (NGS) technologies;
• Analyze controversies in cancer risk assessment and genetic testing including the integration of polygenic risk scores;
• Recognize how scientific advances in Lynch syndrome and other inherited solid tumors and hematologic malignancies can improve the clinical management of patients;
• Discuss how the integration of novel cancer therapies based on genomic alterations in tumor tissue may reveal germline mutations that can guide patient management;
• Recognize the limitations of genomic testing as it relates to both cancer risk as well as therapeutic selection, including variants of uncertain significance and in silico predictions;
• Identify how a globally-informed perspective on experimental therapeutics for rare cancers including immunotherapy can improve patient outcomes;
• Discuss how emerging concepts in cancer interception and cancer risk modifiers including lifestyle and chemoprevention can impact disease management strategies;
• State the ethical, legal, and social implications of genomic testing in diverse populations.

Join for the 9th Annual International Clinical Cancer Genetics and Genomics Conference in conjunction with the Personalized Cancer Care Consortium!